ARTICLE | Company News
Rigel, AstraZeneca deal
June 25, 2012 7:00 AM UTC
Rigel granted AstraZeneca exclusive, worldwide rights to develop and commercialize inhaled Janus kinase (JAK) inhibitor R256. The compound is in preclinical testing to treat moderate to severe chroni...